The EndoNET Trial
Neo-adjuvant endocrine treatment (NET) for post-menopausal women with breast cancer
Specialty: Breast cancer, breast surgery
Status: Open to Recruitment
About EndoNET
Welcome to EndoNET, a clinical trial designed to understand if a period of treatment with hormone therapy prior to surgery reduces the requirement for mastectomy and improves quality of life in post-menopausal women.
EndoNET was identified as a research priority by NICE for post-menopausal women with early breast cancer and the trial is driven by our patient advocates including Independent Cancer Patients’ Voice.
Trial Details
EndoNET is a Phase III, multi-centre trial that evaluates whether endocrine treatment that prevents the production of oestrogens, when taken for 6 months prior to surgery, will shrink the tumour allowing for a reduction in the extent of surgery.
To be considered for the study, patients must be:
- Post-menopausal
- Strongly ER+
- HER2-
- Tumour > 20 mm.
Participants will either be randomised to surgery at 2-4 weeks (up to 8 weeks permitted) or 6 months (+/- 1 month). Participants will complete quality of life questionnaires at intervals during their 15-month participation and rates of breast conservation surgery will be documented.
EndoNET Randomisation
Eligible patients will either be randomised to either surgery at 2-4 weeks (up to 8 weeks permitted) or 6 months (+/- 1 month). Participants will start their endocrine treatment (aromatase inhibitors: letrozole, anastrozole or exemestane) after being randomised:
The endocrine treatment offered in both arms is the same but the timing of surgery differs. This is to see if a longer duration of endocrine treatment before surgery will shrink the tumour to allow for less extensive surgery.
Trial Schema
 |
Prospective Sites
If you are a UK hospital who would be interested in joining the 30+ centres taking part in EndoNET, please contact: endonet@nds.ox.ac.uk to find out more information and request a feasibility form. We are part of the NIHR Associate PI scheme and are on the NIHR Portfolio.
Trial Team
 |
 |
 |
 |
|
Prof. Michael Douek |
Prof. Ramsey Cutress |
Charles Malyon |
Tallulah Chaplain |
Further Information
EndoNET is funded by the National Institute for Health Research HTA Programme.
Visit us on the Association for Breast Surgery website.
 |
 |
 |
 |
 |